Sectors
MDGL
Madrigal Pharmaceuticals, Inc.
482.00
1 x 485.55
1 x 549.24
bid
ask
+
14.68
3.14%
undefined @ 06:04 AM
495.00 +13.00 (2.70%)
| Ytd | -17.23% | |
| 1y | 59.51% |
461.25
day range
485.95
200.63
52 week range
615.00
| Open | 462.15 | Prev Close | 467.32 | Low | 461.25 | High | 485.95 | Mkt Cap | 11.14B |
| Vol | 463.92K | Avg Vol | 361.86K | EPS | -12.89 | P/E | N/A | Forward P/E | 666.67 |
| Beta | -1.05 | Short Ratio | 8.54 | Inst. Own | 107.07% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 516.35 | 200-d Avg | 507.25 | 1yr Est | 679.64 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-03 | 2026-09 | -0.91 | N/A | N/A | N/A |
| 2026-07-30 | 2026-06 | -2.68 | -1.99 | 0.69 | 25.75% |
| 2026-05-06 | 2026-03 | -3.61 | -3.25 | 0.36 | 9.97% |
| 2026-02-19 | 2025-12 | 0.04 | -2.57 | -2.61 | -6525.00% |
| 2025-11-04 | 2025-09 | -2.04 | -5.08 | -3.04 | -149.38% |
| 2025-08-05 | 2025-06 | -3.48 | -1.9 | 1.58 | 45.40% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-11 | B of A Securities | Upgrade | Neutral | Neutral |
| 2026-05-13 | Truist Securities | Upgrade | Buy | Buy |
| 2026-05-07 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-05-07 | Evercore ISI Group | Upgrade | Outperform | Outperform |
| 2026-05-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-02-20 | B of A Securities | Upgrade | Neutral | Neutral |
Profile
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-16 | BAKER BROS ADVISORS, L.P. | Unknown | 0.00 | Stock Award(Grant) |
| 2025-03-12 | CRAVES FREDERICK B | Director | 383.55K | Conversion of Exercise of derivative security |
| 2026-03-05 | DIER MARDI C | Chief Financial Officer | 12.49K | Sale |
| 2026-01-08 | FRIEDMAN PAUL A | Director | 842.70K | Conversion of Exercise of derivative security |
| 2026-03-05 | HUNTSMAN CAROLE A | Officer | 12.69K | Sale |
| 2026-03-05 | KELLEY SHANNON T | General Counsel | 12.14K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Baker Bros Advisors LP | 2.14M | 0.00 | 9.29% |
| 2026-03-30 | HHG PLC | 2.02M | 0.00 | 8.76% |
| 2026-03-30 | RTW INVESTMENTS, LLC | 1.99M | 0.00 | 8.65% |
| 2026-03-30 | venBio Select Advisor LLC | 1.82M | 0.00 | 7.89% |
| 2025-12-30 | Vanguard Group Inc | 1.81M | 0.00 | 7.85% |
| 2026-03-30 | BlackRock Inc | 1.56M | 0.00 | 6.77% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 585.11K | 0.00 | 2.54% |
| 2026-03-30 | Vanguard Health Care Inv | 444.14K | 0.00 | 1.93% |
| 2026-04-29 | Janus Henderson Forty S | 429.42K | 0.00 | 1.86% |
| 2026-03-30 | Janus Concentrated Growth CF | 429.42K | 0.00 | 1.86% |
| 2026-06-29 | Vanguard Small Cap Index | 423.04K | 0.00 | 1.83% |
| 2026-06-29 | Vanguard Small Cap Growth Index Inv | 244.33K | 0.00 | 1.06% |
Split
| Split | Date |
|---|---|
| 1 : 35 | 2016-07-25 |